Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:44 PM
Ignite Modification Date:
2025-12-24 @ 9:44 PM
NCT ID:
NCT05495932
Eligibility Criteria:
Inclusion Criteria:
* Minimum age: 18 years old
* History of severe asthma diagnosed by a physician (according to Global Initiative for Asthma (GINA) criteria)
* Subject on a combination of high-dose (ICS equivalent to 1000 μg beclomethasone) and medium dose inhaled corticosteroid and long acting beta-agonists at least 12 months before inclusion
* Treatment with mepolizumab in line with the Marketing Authorization
* Having received at least 6 doses of mepolizumab (monthly subcutaneous administration)
* Documented initial clinical response to mepolizumab
Exclusion Criteria:
* Other respiratory diseases
* Potential interference from another study
* Immunosuppressive treatment (i.e methotrexate, polyvalent immunoglobulins, other monoclonal antibody for other condition such as cancer; oral and/or inhaled corticosteroids are allowed)
* Populations protected according to the French public health code
* Patient is unavailable, unable or unwilling to attend future visits
* Non-beneficiary of the French national health insurance system
* Lack of informed consent
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05495932
Study Brief:
Protocol Section:
NCT05495932